The structural engineer behind Sydney’s Opal Tower plans to drag insurer Tokio Marine into a lawsuit against two of Icon’s insurers, after discovering another $50 million policy that responds to claims in a class action brought by apartment owners.
Westpac has agreed to pay $1.5 million to settle proceedings brought by ASIC for misleading 141 customers into believing they had purchased add-on insurance.
A case before the Full Court that will revisit the question of whether class actions are managed investment schemes may not resolve all of the funding controversies that have emerged in a class action against franchise giant Retail Food Group, a court has heard.
A barrister who has sued Nine over its coverage of her battle for custody of famed social media pooch Oscar the cavoodle has accused the media company of seeking to delay filing a response to the lawsuit so that it can ‘fish’ for a defence.
Mercedes-Benz will defend ACCC proceedings alleging it exposed consumers to serious injury or death by failing to comply with obligations under a compulsory recall of potentially deadly Takata airbags by arguing the recall was invalid.
The ACCC has expressed preliminary concerns that Spirit Super and Palisade Investment Partners’ proposed $1.2 billion acquisition of the Port of Geelong could substantially lessen competition in Victoria for the supply of bulk cargo port services.
The High Court has declined special leave to members of the Victorian Labor party to challenge a judge’s finding that the pre-selection of ALP candidates in Victorian electorates by federal administrators during their takeover of the state party was lawful.
The structural engineer behind Sydney’s Opal Tower has taken builder Icon’s insurers to court, arguing they should cover its costs in a class action brought on behalf of residents of the ill-fated building and related litigation.
Star Entertainment Group has been hit with a shareholder class action for allegedly painting itself as the “cleanskin” of the gambling industry despite alleged lax compliance and links to money laundering and organised crime, amid a damning public inquiry by the gambling regulator that has led to the resignation of its CEO.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.